Good afternoon :)
Place Order
Add to Watchlist

Eiko Lifesciences Ltd

EIKO

Eiko Lifesciences Ltd

EIKO
Diversified Financials
SmallcapWith a market cap of ₹82 cr, stock is ranked 3,182
High RiskStock is 4.08x as volatile as Nifty
64.398.73% (+5.17)
64.398.73% (+5.17)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Diversified Financials
SmallcapWith a market cap of ₹82 cr, stock is ranked 3,182
High RiskStock is 4.08x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Diversified Financials
SmallcapWith a market cap of ₹82 cr, stock is ranked 3,182
High RiskStock is 4.08x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
131.631.64
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
00

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Narendra Investments Delhi is engaged in investment activities

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 135.27%, vs industry avg of 11.37%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0% to 0.02%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 56.87%, vs industry avg of 24.22%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue0.580.400.510.390.4312.4526.0819.1728.1120.76
Raw Materialssubtract0.000.000.000.000.0010.6725.0513.6627.2019.40
Power & Fuel Costsubtract0.000.000.000.000.000.020.100.040.07
Employee Costsubtract0.100.060.070.020.070.120.230.230.16
Selling & Administrative Expensessubtract0.360.080.110.170.100.200.450.420.47
Operating & Other expensessubtract0.000.00-0.000.000.000.47-1.733.01-1.59
Depreciation/Amortizationsubtract0.000.020.060.060.060.060.560.630.660.41
Interest & Other Itemssubtract0.000.020.050.030.070.090.480.160.150.18
Taxes & Other Itemssubtract0.030.060.030.030.000.220.230.260.230.14
EPS0.260.460.480.180.291.361.010.790.650.45
DPS0.000.220.000.000.000.000.000.000.000.00
Payout ratio0.000.470.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

Apr 20PDF
Feb 10PDF
FY 2022

Annual report

PDF

Investor Presentation

Jul 30PDF
 

Peers & Comparison

Comparing 3 stocks from 
-Diversified Financials

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Eiko Lifesciences Ltd109.111.64
Motilal Oswal Financial Services Ltd23.406.510.37%
Aditya Birla Capital Ltd15.541.81
Cholamandalam Financial Holdings Ltd16.651.330.03%

Price Comparison

Compare EIKO with any stock or ETF
Compare EIKO with any stock or ETF
EIKO
Loading...

Shareholdings

Promoter Holdings Trend

Increased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 6.87%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding31.27%0.00%0.00%0.00%68.73%

Mar 2024

Jun 2024

Sep 2024

Nov 2024

Shareholding History

Dec '23JanMarJunSepNov0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

EIKO has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 20, 2017

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Sep 20, 2017

News & Opinions
Corporate
Eiko Lifesciences to conduct board meeting

Eiko Lifesciences will hold a meeting of the Board of Directors of the Company on 25 November 2024Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Earnings
Eiko Lifesciences standalone net profit rises 75.00% in the September 2024 quarter

Net profit of Eiko Lifesciences rose 75.00% to Rs 0.21 crore in the quarter ended September 2024 as against Rs 0.12 crore during the previous quarter ended September 2023. Sales rose 20.75% to Rs 7.74 crore in the quarter ended September 2024 as against Rs 6.41 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales7.746.41 21 OPM %4.655.46 - PBDT0.450.32 41 PBT0.290.16 81 NP0.210.12 75 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Eiko Lifesciences to discuss results

Eiko Lifesciences will hold a meeting of the Board of Directors of the Company on 19 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Eiko Lifesciences to convene AGM

Eiko Lifesciences announced that the 47th Annual General Meeting (AGM) of the company will be held on 28 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Eiko Lifesciences standalone net profit rises 337.50% in the June 2024 quarter

Net profit of Eiko Lifesciences rose 337.50% to Rs 0.35 crore in the quarter ended June 2024 as against Rs 0.08 crore during the previous quarter ended June 2023. Sales rose 65.13% to Rs 10.75 crore in the quarter ended June 2024 as against Rs 6.51 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales10.756.51 65 OPM %3.814.15 - PBDT0.640.27 137 PBT0.470.11 327 NP0.350.08 338 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Eiko Lifesciences to discuss results

Eiko Lifesciences will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live